心臟再同步化治療(CRT)的全球市場 - 市場規模(各市場區隔)，佔有率，法規，償付，治療，預測(～2033年)

本報告提供全球心臟再同步化治療(CRT)市場相關調查分析，提供主要企業市場佔有率，主要趨勢，創新的產品與技術，競爭情形等資訊。

市場模式的主要內容如下列。

已上市的心臟再同步化治療(CRT)與不斷變化的競爭格局

• 主要的產業趨勢的考察
• 心臟再同步化治療(CRT)市場區隔的年度收益與市場預測(2015年～2033年)
• 有關各市場區隔的整體治療數，台數，平均銷售價格，市場金額的詳細的資料

世界，地區，國家層級的市場固有的考察

• 各地區分類的全球趨勢之特定市場定性資訊和國家/地區考慮因素
• 心臟再同步化治療(CRT)市場SWOT分析
• 心臟再同步化治療(CRT)市場競爭動態的考察和趨勢

透過對醫療保健系統的真實、全面的了解來促進市場理解。市場進入部分還提供有關報銷政策和監管環境的信息，使您能夠更深入地研究市場動態。

• 各國醫療制度概要
• 各國償付政策
• 各國醫療技術相關法規形勢

對象企業

• Medtronic Plc
• Abbott Laboratories
• Biotronik SE & Co KG
• Boston Scientific Corp
• MicroPort Scientific Corp
• EBR Systems Inc
• 其他

Cardiac Resynchronisation Therapy (CRT) Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033 is built to visualize quantitative and qualitative market trends within Cardiovascular Devices therapeutic area.

Cardiac Resynchronisation Therapy (CRT) is a device used for the treatment of heart failure-induced conduction disturbances and ventricular dyssynchrony. When used in combination with stable, optimal medical therapy, CRT is designed to reduce symptoms and improve cardiac function by restoring the mechanical sequence of ventricular activation and contraction.

Cardiac Resynchronisation Therapy has become a widely accepted option which restores a better physiological pattern of contractions to the desynchronized hearts. Secondary sources indicate that CRT has proven to reduce the morbidity and mortality in patients at a large scale. Ventricular Dyssynchrony, Interventricular Conduction Delay, Ventricular Tachycardia and Ventricular Fibrillation have become the basis of Cardiac Resynchronisation Therapy as it leads to significant improvements in symptoms and survival of patients.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. The interactive excel deliverable covers value, volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are -

Currently marketed Cardiac Resynchronisation Therapy (CRT) and evolving competitive landscape -

• Insightful review of the key industry trends.
• Annualized total Cardiac Resynchronisation Therapy (CRT) market revenue by segment and market outlooks from 2015-2033.
• Granular data on total procedures, units, average selling prices and market values by segment.

Global, Regional and Country level market specific insights -

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Cardiac Resynchronisation Therapy (CRT) market.
• Competitive dynamics insights and trends provided for Cardiac Resynchronisation Therapy (CRT) market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Medtronic Plc, Abbott Laboratories, Biotronik SE & Co KG, Boston Scientific Corp, MicroPort Scientific Corp, EBR Systems Inc, and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the Cardiac Resynchronisation Therapy (CRT) marketplace to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products, by identifying key companies.
• Develop business strategies by understanding the trends shaping and driving Cardiac Resynchronisation Therapy (CRT) market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Cardiac Resynchronisation Therapy (CRT) market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific Cardiac Resynchronisation Therapy (CRT) market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.